Dexcom: CONNECT supports CGM use in T2D NIT

研报英文原文证据摘录

Dexcom: CONNECT supports CGM use in T2D NIT

Accessible version

Dexcom

CONNECT supports CGM use in T2D NIT

Maintain Rating: BUY | PO: 80.00 USD | Price: 72.86 USD

Positive CONNECT data supports T2D NIT coverage 07 June 2026

CONNECT data presented on Saturday showed better clinical outcomes with CGM vs. Equity

routine care across all metrics in Type 2 diabetes patients not using insulin (T2D NIT).

Travis Steed

Significantly greater reductions in HbA1c were seen with CGM and an impressive 97% Research Analyst

utilization rate supports patient benefit. Importantly, CGM improved clinical outcomes BofAS travis.steed@bofa.com

across all baseline therapies (many T2D patients are on glucose lowering medication).

Stephanie Elghazi

We think the results support use of CGM in the T2D NIT population and could help Research Analyst

establish coverage for use in the T2D NIT population. We maintain our Buy rating. BofAS stephanie.elghazi@bofa.com

Superior HbA1c outcomes with CGM in T2D NIT patients GraciaResearchMahoneyAnalyst

CGM significantly reduced HbA1c levels (primary endpoint) to a greater degree vs. BofAS gracia.mahoney@bofa.com

routine care. At 26wks, HbA1c levels in the CGM arm were 0.9% lower than routine care

Rei Tan

(p<0.001). This was notable given the treatment difference is on top of the 0.7% Research Analyst

reduction from baseline already seen in the routine care arm at 26wks. CGM consistently BofASrei.tan@bofa.com

lowered HbA1c to a greater degree vs. routine care regardless of baseline HbA1c. Enjia Cao

Patients with higher baseline levels saw greater reduction in HbA1c in both arms and a Research Analyst

larger treatment difference favoring CGM. CGM also significantly outperformed routine BofASenjia.cao@bofa.com